[{"orgOrder":0,"company":"Hikma Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Dobutamine Hydrochloride","moa":"||Adrenergic-beta receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Hikma Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Hikma Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Hikma Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"The Young Investigator Group of Cardiovascular Research","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ivabradine Hydrochloride","moa":"||Potassium\/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"The Young Investigator Group of Cardiovascular Research","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"The Young Investigator Group of Cardiovascular Research \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"The Young Investigator Group of Cardiovascular Research \/ Inapplicable"},{"orgOrder":0,"company":"Rigshospitalet","sponsor":"Novo Nordisk | Simon Spies Fonden | Helge Peetz og Verner Peetz og hustru Vilma Peetz Legat","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"||Interleukin-6 receptor alpha subunit","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Rigshospitalet","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rigshospitalet \/ Novo Nordisk | Simon Spies Fonden | Helge Peetz og Verner Peetz og hustru Vilma Peetz Legat","highestDevelopmentStatusID":"8","companyTruncated":"Rigshospitalet \/ Novo Nordisk | Simon Spies Fonden | Helge Peetz og Verner Peetz og hustru Vilma Peetz Legat"},{"orgOrder":0,"company":"Northwell Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Dobutamine Hydrochloride","moa":"||Beta-2 adrenergic receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Northwell Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Northwell Health \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Northwell Health \/ Inapplicable"}]

Find Clinical Drug Pipeline Developments & Deals for Dobutamine

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Dobutamine injection stimulates heart muscle and improves blood flow by helping the heart pump better, which is used short-term to treat cardiac decompensation due to weakened heart muscle.

                          Product Name : Dobutamine-Generic

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          June 14, 2023

                          Lead Product(s) : Dobutamine Hydrochloride,Inapplicable

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          The Young Investigator Group of Cardiovascular Research

                          Country arrow
                          EPSC
                          Not Confirmed

                          The Young Investigator Group of Cardiovascular Research

                          Country arrow
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          October 26, 2022

                          Lead Product(s) : Ivabradine Hydrochloride,Dobutamine Hydrochloride

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          Rigshospitalet

                          Country arrow
                          EPSC
                          Not Confirmed

                          Rigshospitalet

                          Country arrow
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Antibody

                          Upfront Cash : Inapplicable

                          April 28, 2022

                          Lead Product(s) : Tocilizumab,Dobutamine Hydrochloride,Sodium Chloride

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase II

                          Sponsor : Novo Nordisk | Simon Spies Fonden | Helge Peetz og Verner Peetz og hustru Vilma Peetz Legat

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          Northwell Health

                          Country arrow
                          EPSC
                          Not Confirmed

                          Northwell Health

                          Country arrow
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          January 30, 2020

                          Lead Product(s) : Dobutamine Hydrochloride,Inapplicable

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          Fundacion para la Investigacion Biomedica del Hospital Universitario la Paz

                          Country arrow
                          EPSC
                          Not Confirmed

                          Fundacion para la Investigacion Biomedica del Hospital Universitario la Paz

                          Country arrow
                          EPSC
                          Not Confirmed

                          Lead Product(s) : Dobutamine Hydrochloride,Inapplicable

                          Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                          Study Phase : Phase I/ Phase II

                          Sponsor : Hospital Universitario La Paz | Brighton and Sussex University Hospitals NHS Trust | University of Luebeck | Servicio Vasco de Salud Osakidetza | University of Liverpool | Vest Children’s Hospital | Datteln University Witten-Herdecke | Iuliu Hatieganu Uni

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          October 17, 2017

                          Lead Product(s) : Dobutamine Hydrochloride,Inapplicable

                          Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Hospital Universitario La Paz | Brighton and Sussex University Hospitals NHS Trust | University of Luebeck | Servicio Vasco de Salud Osakidetza | University of Liverpool | Vest Children’s Hospital | Datteln University Witten-Herdecke | Iuliu Hatieganu Uni

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          Cambridge University Hospitals NHS Foundation Trust

                          Country arrow
                          EPSC
                          Not Confirmed

                          Cambridge University Hospitals NHS Foundation Trust

                          Country arrow
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          April 04, 2017

                          Lead Product(s) : Salbutamol Sulphate,Nicardipine Hydrochloride,Dobutamine Hydrochloride

                          Therapeutic Area : Pharmacology/Toxicology

                          Highest Development Status : Phase I

                          Sponsor : University of Cambridge | AstraZeneca

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank